Tumor Necrosis Factor-α Blockers in SAPHO Syndrome

被引:75
作者
Ben Abdelghani, Kaouther [1 ]
Dran, Delphine Gerard [1 ]
Gottenberg, Jacques-Eric [2 ]
Morel, Jacques [1 ]
Sibila, Jean [2 ]
Combe, Bernard [1 ]
机构
[1] Lapeyronie Hosp, Dept Immunorheumatol, Montpellier, France
[2] Hautepierre Hosp, Dept Rheumatol, Strasbourg, France
关键词
SAPHO SYNDROME; PALMOPLANTAR PUSTULOSIS; INFLIXIMAB; ETANERCEPT; ADALIMUMAB; TUMOR NECROSIS FACTOR-alpha BLOCKERS; HYPEROSTOSIS-OSTEITIS SAPHO; ANTIBIOTIC-THERAPY; INFLIXIMAB; PUSTULOSIS; ACNE; SYNOVITIS; DISEASES; INDUCE;
D O I
10.3899/jrheum.091086
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To analyze the clinical efficacy of anti-tumor necrosis factor-alpha (TNF-alpha) therapy in treatment of synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome, we describe cases of refractory SAPHO syndrome and review cases treated with anti-TNF-alpha reported in the literature. Methods. We describe 6 cases of patients with SAPHO syndrome treated with anti-TNF-alpha between 2004 and 2008. Therapeutic response was evaluated according to improvement in pain score, amelioration of disease activity, and improvement in function. The efficacy of treatment was considered to be reduced need for analgesics and/or antiinflammatory therapy. Results. In our series, 4 patients received infliximab, 1 etanercept, and 1 adalimumab. These treatments brought clinical response in 4 patients (66.6%): response was sustained with infliximab in 1 case for 7 months; with adalimumab in another case for 22 months; and with etanercept in 2 cases for I and 42 months, respectively. In contrast, 2 other patients showed no response to infliximab. Improvement was initially temporary after infusions 1 and 2, then pain recurred at Week 14. Skin lesions were healed in 3 of 4 cases, but recurred or worsened in 2 cases, after infusion 2 of infliximab. Treatment was generally well tolerated. Paradoxical psoriasis was noted in 2 cases and urticaria in 1. Conclusion. Given our results and those from the literature, TNF-alpha blockers should be considered in the therapeutic strategy of refractory cases of SAPHO syndrome, despite their effect seeming less impressive than in other spondyloarthropathies. (First Release May 15 2010; J Rheumatol 2010; 37:1699-704; doi:10.3899/jrheum.091086)
引用
收藏
页码:1699 / 1704
页数:6
相关论文
共 24 条
[1]   SAPHO syndrome treated with pamidronate: an open-label study of 10 patients [J].
Amital, H ;
Applbaum, YH ;
Aamar, S ;
Daniel, N ;
Rubinow, A .
RHEUMATOLOGY, 2004, 43 (05) :658-661
[2]  
ASMUSSEN KH, 2003, ARTHRITIS RHEUM S, V48
[3]   Efficacy of antibiotic therapy for SAPHO syndrome is lost after its discontinuation: an interventional study [J].
Assmann, Gunter ;
Kueck, Olaf ;
Kirchhoff, Timm ;
Rosenthal, Herbert ;
Voswinkel, Jan ;
Pfreundschuh, Michael ;
Zeidler, Henning ;
Wagner, Annette D. .
ARTHRITIS RESEARCH & THERAPY, 2009, 11 (05)
[4]  
Boonen A, 1997, REV RHUM, V64, P424
[5]  
BOUCHAUDCHABOT A, 1994, REV RHUM ENGL ED, P661
[6]  
Brockbank JE, 2001, J RHEUMATOL, V28, P62
[7]  
CHAMOT AM, 1987, REV RHUM, V54, P187
[8]   Successful treatment of chronic recurrent multifocal osteomyelitis with tumor necrosis factor-α blockage [J].
Deutschmann, A ;
Mache, CJ ;
Bodo, K ;
Zebedin, D ;
Ring, E .
PEDIATRICS, 2005, 116 (05) :1231-1233
[9]   SAPHO syndrome: A long-term follow-up study of 120 cases [J].
Hayem, G ;
Bouchaud-Chabot, A ;
Benali, K ;
Roux, S ;
Palazzo, E ;
Silbermann-Hoffman, O ;
Kahn, MF ;
Meyer, O .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 1999, 29 (03) :159-171
[10]   Acne fulminans with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with infliximab [J].
Iqbal, M ;
Kolodney, MS .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (05) :S118-S120